Related Experiment Video
Updated: Feb 4, 2026

In Vitro Cellular Activity Evaluation of the Nanoemulsion Vaccine Adjuvant Ophiopogonin D
Published on: December 9, 2022
HER1-based vaccine: Simultaneous activation of humoral and cellular immune response
Gretchen Bergado Báez1, Diana R Hernández Fernández1, Zaima Mazorra Herrera2
1Tumor Immunology Direction, Center of Molecular Immunology, La Habana, Cuba.
Abstract:
The human epidermal growth factor receptor 1 (HER1) is a tumor-associated antigen that has been validated as a clinical target for several passive, non-immune therapies currently approved for the treatment of epithelial tumors. HER1 is an oncogene that not only promotes tumor progression and survival, but also immune escape. Its overexpression in some epithelial malignancies has been correlated with a poor prognosis. We developed an approach to target HER1 by specific active immunotherapy, recognizing the extracellular domain of the receptor, using a combination of VSSP and Montanide ISA 51 as adjuvants. We summarize the results obtained with this vaccine in both the preclinical and clinical settings, emphasizing the importance of the induction of both humoral and cellular responses for the success of cancer vaccines as safe therapeutic alternatives for the treatment of cancer.
More Related Videos
Related Concept Videos
Humoral Immune Responses
Vaccinations
Active versus Passive Immunity
Active Immunity
Active immunity refers to the resistance one develops...
Inflammatory Response I: Vascular and Cellular
Cell-mediated Immune Responses
Cells of the Adaptive Immune Response

